tegaserod

Trade name: zelnorm

Small moleculeapproved

Approved

Jul 24, 2002

Tegaserod (3‐(5‐methoxy‐1H‐indol‐3ylmethylene)‐N‐pentyl‐carbazimidamide), an aminoguanidine indole derivative of serotonin, is a selective partial agonist highly selective for 5‐HT4 receptor with an affinity constant in the nanomolar range. Tegaserod, by acting as an agonist at neuronal 5-HT4 receptors, triggers the release of further neurotransmitters such as calcitonin gene-related peptide from sensory neurons. The activation of 5-HT4 receptors in the gastrointestinal tract stimulates the peristaltic reflex and intestinal secretion, as well as inhibits visceral sensitivity. In vivo studies showed that tegaserod enhanced basal motor activity and normalized impaired motility throughout the gastrointestinal tract. Zelnorm® (tegaserod maleate) is indicated for the short-term treatment of women with irritable bowel syndrome (IBS) whose primary bowel symptom is constipation. In addition Zelnorm® is indicated for the treatment of patients less than 65 years of age with chronic idiopathic constipation. — NCATS

Clinical trial activity

25 trials · 7 clinical orgs · 3 marketing orgs

Phase 1
0
Phase 2
15
Phase 3
14
Phase 4
6

Earliest trial started Jun 1, 2003 (NCT00171418)

Timeline

2000s

  1. Jul 24, 2002

    Novartis — Earliest FDA Approval

  2. Jul 24, 2002

    Novartis — NDA Organization

  3. Jul 24, 2002

    US WorldMeds — NDA Secondary Org

  4. Jul 24, 2002

    Alfasigma S.p.A. — Marketing Organization

  5. Jul 24, 2002

    Alfasigma S.p.A. — NDA Secondary Org

  6. Jan 1, 2003

    Novartis — Earliest Phase 3 Sponsor(trial)

  7. Jan 1, 2004

    Novartis — Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedPriority reviewJul 24, 2002

Chemistry & pharmacology

Loading structure…

SMILES

CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12
Mol. weight
301.39 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 1-(((5-methoxyindol-3-yl)methylene)amino)-3-pentylguanidine
  • 1-(((5-methoxyindol-3-yl)methylene)amino)-3-pentylguanidine
  • 5-methoxyindol-3-carboxaldehyde amino(pentylamino)methylenehydrazone hydrogen maleate
  • htf 919
  • htf 919
  • htf-919
  • htf-919
  • sdz htf 919
  • sdz htf-919
  • sdz-htf-919
  • sdz-htf-919
  • tegaserod
  • tegaserod
  • tegaserod
  • tegaserod
  • tegaserod
  • tegaserod
  • tegaserod
  • tegaserod
  • tegaserod
  • tegaserod
  • tégasérod
  • tégasérod
  • tegaserod maleate
  • tegaserod maleate
  • tegaserod maleate
  • tegaserod maleate
  • tegaserod maleate
  • tegaserod maleate
  • tegaserod maleate
  • tegaserodum
  • tegaserodum
  • zelmac
  • zelmac
  • zelmac
  • zelnorm
  • zelnorm
  • zelnorm
  • zelnorm
  • zelnorm

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00511771N/AAug 3, 2007Novartis
NCT00414024Phase 3Feb 1, 2007Novartis
NCT00390975Phase 4Jan 1, 2007Novartis
NCT00399659Phase 3Nov 1, 2006Novartis
NCT00365820Phase 2/Phase 3 (Phase 3)Jul 1, 2006Novartis
NCT00348634Phase 4Jul 1, 2006Novartis, Temple University, University of Michigan
NCT00277550Phase 4Jan 13, 2006Mayo Clinic, Novartis
NCT00171522Phase 4May 1, 2005Novartis
NCT00171457Phase 3Apr 1, 2005Novartis
NCT00171470Phase 3Apr 1, 2005Novartis
NCT00139568Phase 3Feb 1, 2005Novartis
NCT00563758N/ADec 1, 2004Government of Hong Kong, Novartis, The University of Hong Kong
NCT00171431Phase 3Nov 1, 2004Novartis
NCT00563615N/ANov 1, 2004Government of Hong Kong, Novartis, University of Toronto
NCT00232037Phase 3Sep 1, 2004Novartis
NCT00232102Phase 3Sep 1, 2004Novartis
NCT00232089Phase 3May 1, 2004Novartis
NCT00142974Phase 2May 1, 2004Novartis
NCT00149877Phase 4Apr 1, 2004Novartis
NCT00142987Phase 4Apr 1, 2004Novartis
Showing 20 of 25 trials
Page 1 / 2

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
NovartisFor profit252342003
Government of Hong KongGovernment2212004
Mayo ClinicAcademic/Hospital1012006
Temple UniversityAcademic/Hospital1012006
The University of Hong KongAcademic/Hospital1012004
University of MichiganAcademic/Hospital1012006
University of TorontoAcademic/Hospital1012004
7 organizations
Page 1 / 1

Marketing (4)

OrganizationOrg typeRelationshipDate
Alfasigma S.p.A.For profitMKTGJul 24, 2002
Alfasigma S.p.A.For profitNDA2Jul 24, 2002
NovartisFor profitNDAJul 24, 2002
US WorldMedsFor profitNDA2Jul 24, 2002